Radiation therapy

Lore & Background

Radiation therapy, also known as radiotherapy, employs ionizing radiation, typically generated by a linear particle accelerator, to kill or control malignant cell growth. Its primary mechanism involves damaging the DNA of cancerous tissue, which leads to cellular death. To protect surrounding healthy tissue, such as skin or organs that the radiation must traverse, shaped beams are directed from multiple angles so they converge on the tumor, resulting in a much higher absorbed dose there. The treatment fields may also encompass nearby lymph nodes if they are clinically or radiologically involved, or if there is a risk of subclinical spread. A margin of normal tissue around the tumor is always included to compensate for daily positioning uncertainties and internal motion, such as breathing or bladder filling. The medical specialty responsible for prescribing this treatment is radiation oncology, distinct from radiology, which uses radiation for imaging and diagnosis. A physician in this field is a radiation oncologist, while the practicing radiographer is a therapeutic radiographer. Radiation therapy can be curative for localized cancers, used as adjuvant therapy to prevent recurrence after surgery, or as palliative care for symptom relief when cure is not possible. It is often combined with surgery, chemotherapy, hormone therapy, or immunotherapy. Different cancers exhibit varying radiosensitivity: leukemias and lymphomas are highly radiosensitive, while most epithelial cancers require higher doses (60–70 Gy) for radical cure. Some cancers, like renal cell cancer and melanoma, are notably radioresistant, though radiation remains a palliative option. Modern treatment relies on CT scans for precise tumor identification and dose calculation, with small skin marks guiding field placement.

Reader's Guide

Its significance lies in its versatility: it can be curative for localized tumors (e.g., non-melanoma skin cancer, head and neck cancer, breast cancer, prostate cancer), adjuvant after surgery, neoadjuvant before surgery, or palliative for symptom relief. The response of a cancer to radiation is described by its radiosensitivity, with highly radiosensitive cancers (leukemias, most lymphomas) killed by modest doses, while moderately radiosensitive epithelial cancers require 60–70 Gy. Radioresistant cancers like melanoma and renal cell cancer may still be treated palliatively. Modern techniques such as image-guided radiation therapy and daily MR-guided adaptive radiotherapy improve precision by correcting for positional and anatomical changes. Side effects are dose-dependent and limited to the treated area; serious complications occur in about 5% of cases. Radiation therapy also has applications in non-malignant conditions, though use is limited by concerns about radiation-induced cancers.

Did You Know?

• Radiation therapy may be used as palliative treatment when cure is not possible, aiming for local disease control or symptomatic relief.
• Total body irradiation (TBI) is a technique used to prepare the body for a bone marrow transplant.
• Brachytherapy places a radioactive source inside or next to the treatment area, minimizing exposure to healthy tissue.
• Radiosensitizing drugs such as cisplatin, nimorazole, and cetuximab can enhance the effectiveness of radiation therapy.

How Radiation Targets and Damages Cancer Cells

Ionizing radiation works by inflicting damage on the DNA within malignant tissue, ultimately triggering cell death. Because the beams must traverse healthy structures like skin and internal organs to reach a deep-seated tumor, clinicians employ a geometric strategy: multiple shaped beams are directed from different angles so they converge precisely at the tumor site. This intersection dramatically amplifies the absorbed dose at the target while keeping surrounding tissue exposure comparatively low. The treatment field is not limited to the visible tumor alone; draining lymph nodes that show clinical or radiological involvement, or that carry a risk of harboring subclinical spread, are often incorporated. A margin of healthy tissue is deliberately included around the tumor to compensate for daily uncertainties—respiratory motion, changes in bladder volume, and slight shifts in external skin marks relative to the actual tumor position. This careful geometric planning is what allows a single modality to be both potent against cancer and tolerable to the patient.

Treatment Intent and the Spectrum of Clinical Use

Radiation therapy is far from a one-size-fits-all intervention. Its precise purpose—whether curative, adjuvant to prevent recurrence after surgery, neoadjuvant to shrink a tumor before other treatments, or palliative to ease symptoms when cure is unattainable—depends on the tumor's type, location, stage, and the patient's overall health. In the United States, roughly half of the 1.2 million invasive cancer cases diagnosed in 2022 incorporated radiation into their treatment pathway. It is frequently combined with chemotherapy, surgery, hormone therapy, or immunotherapy, and its synergistic relationship with chemotherapy has been exploited before, during, and after systemic treatment. Beyond malignancy, radiation finds application in conditions such as trigeminal neuralgia, acoustic neuromas, severe thyroid eye disease, pterygium, pigmented villonodular synovitis, keloid scar prevention, vascular restenosis, and heterotopic ossification, though concern about radiation-induced secondary cancers tempers its use in these settings. Total body irradiation serves a distinct role in conditioning patients for bone marrow transplantation.

Radiosensitivity and the Limits of Curability

Not all cancers respond to radiation in the same way, and understanding this spectrum is central to treatment planning. Leukemias, most lymphomas, and germ cell tumors are highly radiosensitive, meaning modest doses can rapidly kill their cells. The bulk of epithelial cancers fall into a moderate-sensitivity category, typically requiring doses in the 60-to-70-gray range for a radical cure. At the other extreme, renal cell carcinoma and melanoma are generally radioresistant, though radiation remains a palliative option for metastatic melanoma, and emerging combinations with immunotherapy show promise. Crucially, laboratory radiosensitivity does not equal clinical curability. Leukemias, despite being highly radiosensitive, are disseminated throughout the body and therefore not curable with radiation alone. Conversely, a localized lymphoma or an early-stage breast, prostate, cervical, or non-small-cell lung cancer can be radically treated. With the exception of oligometastatic disease, widespread metastatic cancers remain beyond the reach of radiation because the modality cannot safely treat the entire body.

The Specialty, the Team, and Modern Delivery

Radiation oncology is the dedicated medical subspecialty responsible for prescribing and overseeing radiation treatment, and it is distinct from radiology, which focuses on imaging and diagnosis. A radiation oncologist determines the treatment intent and prescribes the plan, while a therapeutic radiographer handles the practical delivery of each session. The equipment at the center of most treatments is a linear particle accelerator, which generates the high-energy beams needed for precise external-beam therapy. Modern planning begins with a CT scan that maps the tumor and adjacent normal anatomy, enabling complex dose calculations. Patients receive small skin marks and are fitted with custom-molded masks or cushions to ensure they can be repositioned identically for every session. Image-guided radiation therapy adds an imaging check before each treatment to correct any positional drift, and newer MR-guided adaptive techniques extend this principle by allowing the high-dose region to be conformed more tightly to the tumor shape, reducing unnecessary exposure to surrounding structures.

Gallery